Welcome to our dedicated page for Biocardia SEC filings (Ticker: BCDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCardia, Inc. SEC filings document a clinical-stage biotechnology and medical-device business focused on cell therapies and related delivery technologies for cardiovascular and pulmonary disease. Recent Form 8-K reports cover Regulation FD disclosures and other events involving CardiAMP clinical data, FDA and PMDA regulatory interactions, the Helix transendocardial delivery catheter, and patent protection for Heart3D Fusion Imaging software.
The company’s filings also record annual operating results, research and development activity, liquidity-related financial disclosures, and Nasdaq continued-listing compliance matters. These documents frame BCDA’s public-company record around product-development programs, regulatory pathways, intellectual property, capital and listing status, risk disclosures, and corporate reporting obligations.
BioCardia (BCDA) announced the first patient was enrolled at the University of Wisconsin School of Medicine and Public Health in its ongoing Phase 3 CardiAMP HF II clinical trial. The update was disclosed under Item 8.01 as a furnished report, and a press release is included as Exhibit 99.1 dated October 30, 2025. The information is furnished, not filed, under the Exchange Act.
BioCardia, Inc. filed an amended Q2 2025 10‑Q solely to add the CEO/CFO certifications omitted from the original filing; no other changes were made.
For the quarter ended June 30, 2025, the company reported a net loss of $2.049 million on operating expenses of $2.051 million. Cash and cash equivalents were $980,000 and stockholders’ equity was a deficit of $(1.886) million. Management states there is “substantial doubt” about continuing as a going concern, noting existing cash is not sufficient beyond October 2025. Shares outstanding were 5,504,802 as of June 30, 2025.
Research and development expense was $1.368 million and selling, general and administrative was $683,000. Subsequent to quarter‑end, the company updated its ATM capacity on July 8, 2025 and sold 296,422 shares for gross proceeds of $769,000 through August 8, 2025. The company also disclosed a Nasdaq notice with an extension to regain equity compliance by September 29, 2025. There were 5,801,224 common shares outstanding as of August 8, 2025.
BCDA filed a prospectus supplement updating its at‑the‑market offering program for common stock through H.C. Wainwright & Co. The supplement sets a new maximum aggregate amount of $5,309,253 that may be sold under the program, after effectiveness and subject to offering conditions.
The company notes it has previously received approximately $3.9 million of gross proceeds from sales under the same program. Eligibility is based on an aggregate market value of non‑affiliate shares of approximately $20.1 million, calculated using 8,846,053 non‑affiliate shares at a $2.27 per‑share price as of September 11, 2025, and is constrained by Form S‑3 General Instruction I.B.6 (one‑third cap). During the 12‑month period ending on the date hereof, the company sold approximately $1.4 million pursuant to I.B.6.
BioCardia, Inc. set its 2025 Annual Meeting of Stockholders for Tuesday, December 2, 2025 at 9:00 a.m. Pacific Time, to be held at Wilson Sonsini Goodrich & Rosati in Palo Alto, California. The company established the close of business on October 8, 2025 as the record date for stockholders entitled to receive notice of and vote at the meeting.
Stockholders who wish to submit proposals for inclusion in the company’s proxy statement under SEC Rule 14a-8, nominate directors, or bring other business at the meeting must ensure their notices are received at BioCardia’s Sunnyvale headquarters by October 17, 2025, and comply with SEC rules, Delaware law, and the company’s bylaws. Stockholders intending to use the universal proxy process to solicit proxies for their own director nominees must also provide the required Rule 14a-19 notice by October 17, 2025.
BioCardia, Inc. announced that on October 2, 2025 it received formal written notice from The Nasdaq Stock Market staff that the company has regained compliance with Listing Rule 5550(b)(1). As a result, the company's common stock will continue to be listed on The Nasdaq Stock Market. The filing states a press release describing the action is attached as Exhibit 99.1 to the current report. The notice signals Nasdaq’s staff has accepted whatever corrective steps the company previously took to meet the Equity Rule and preserves the company’s ongoing access to Nasdaq’s market for its common shares.
BioCardia, Inc. Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC reports shared beneficial ownership of 557,179 shares of BioCardia common stock, representing 4.99% of the class as of the close of business on September 24, 2025. The filing explains these shares are issuable upon exercise of a warrant (Intracoastal Warrant 1) and that additional warrants and issuances exist but contain blocker provisions that prevent exercise to the extent doing so would exceed a 4.99% ownership threshold. The reporting persons state the holdings were not acquired to influence control.
BioCardia, Inc. Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC reports shared beneficial ownership of 557,179 shares of BioCardia common stock, representing 4.99% of the class as of the close of business on September 24, 2025. The filing explains these shares are issuable upon exercise of a warrant (Intracoastal Warrant 1) and that additional warrants and issuances exist but contain blocker provisions that prevent exercise to the extent doing so would exceed a 4.99% ownership threshold. The reporting persons state the holdings were not acquired to influence control.
BioCardia, Inc. Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC reports shared beneficial ownership of 557,179 shares of BioCardia common stock, representing 4.99% of the class as of the close of business on September 24, 2025. The filing explains these shares are issuable upon exercise of a warrant (Intracoastal Warrant 1) and that additional warrants and issuances exist but contain blocker provisions that prevent exercise to the extent doing so would exceed a 4.99% ownership threshold. The reporting persons state the holdings were not acquired to influence control.
BioCardia, Inc. Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC reports shared beneficial ownership of 557,179 shares of BioCardia common stock, representing 4.99% of the class as of the close of business on September 24, 2025. The filing explains these shares are issuable upon exercise of a warrant (Intracoastal Warrant 1) and that additional warrants and issuances exist but contain blocker provisions that prevent exercise to the extent doing so would exceed a 4.99% ownership threshold. The reporting persons state the holdings were not acquired to influence control.
BioCardia, Inc. Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC reports shared beneficial ownership of 557,179 shares of BioCardia common stock, representing 4.99% of the class as of the close of business on September 24, 2025. The filing explains these shares are issuable upon exercise of a warrant (Intracoastal Warrant 1) and that additional warrants and issuances exist but contain blocker provisions that prevent exercise to the extent doing so would exceed a 4.99% ownership threshold. The reporting persons state the holdings were not acquired to influence control.
BioCardia, Inc. Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC reports shared beneficial ownership of 557,179 shares of BioCardia common stock, representing 4.99% of the class as of the close of business on September 24, 2025. The filing explains these shares are issuable upon exercise of a warrant (Intracoastal Warrant 1) and that additional warrants and issuances exist but contain blocker provisions that prevent exercise to the extent doing so would exceed a 4.99% ownership threshold. The reporting persons state the holdings were not acquired to influence control.
BioCardia, Inc. Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC reports shared beneficial ownership of 557,179 shares of BioCardia common stock, representing 4.99% of the class as of the close of business on September 24, 2025. The filing explains these shares are issuable upon exercise of a warrant (Intracoastal Warrant 1) and that additional warrants and issuances exist but contain blocker provisions that prevent exercise to the extent doing so would exceed a 4.99% ownership threshold. The reporting persons state the holdings were not acquired to influence control.
BioCardia, Inc. Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC reports shared beneficial ownership of 557,179 shares of BioCardia common stock, representing 4.99% of the class as of the close of business on September 24, 2025. The filing explains these shares are issuable upon exercise of a warrant (Intracoastal Warrant 1) and that additional warrants and issuances exist but contain blocker provisions that prevent exercise to the extent doing so would exceed a 4.99% ownership threshold. The reporting persons state the holdings were not acquired to influence control.
BioCardia, Inc. Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC reports shared beneficial ownership of 557,179 shares of BioCardia common stock, representing 4.99% of the class as of the close of business on September 24, 2025. The filing explains these shares are issuable upon exercise of a warrant (Intracoastal Warrant 1) and that additional warrants and issuances exist but contain blocker provisions that prevent exercise to the extent doing so would exceed a 4.99% ownership threshold. The reporting persons state the holdings were not acquired to influence control.
BioCardia, Inc. Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC reports shared beneficial ownership of 557,179 shares of BioCardia common stock, representing 4.99% of the class as of the close of business on September 24, 2025. The filing explains these shares are issuable upon exercise of a warrant (Intracoastal Warrant 1) and that additional warrants and issuances exist but contain blocker provisions that prevent exercise to the extent doing so would exceed a 4.99% ownership threshold. The reporting persons state the holdings were not acquired to influence control.
BioCardia, Inc. Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC reports shared beneficial ownership of 557,179 shares of BioCardia common stock, representing 4.99% of the class as of the close of business on September 24, 2025. The filing explains these shares are issuable upon exercise of a warrant (Intracoastal Warrant 1) and that additional warrants and issuances exist but contain blocker provisions that prevent exercise to the extent doing so would exceed a 4.99% ownership threshold. The reporting persons state the holdings were not acquired to influence control.
BioCardia, Inc. Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital, LLC reports shared beneficial ownership of 557,179 shares of BioCardia common stock, representing 4.99% of the class as of the close of business on September 24, 2025. The filing explains these shares are issuable upon exercise of a warrant (Intracoastal Warrant 1) and that additional warrants and issuances exist but contain blocker provisions that prevent exercise to the extent doing so would exceed a 4.99% ownership threshold. The reporting persons state the holdings were not acquired to influence control.
BioCardia, Inc. filed a Current Report stating that, as of the report date, it believes it has regained compliance with Nasdaq's minimum $2.5 million stockholders' equity requirement for continued listing. The company notes that stockholders' equity exceeds $2.5 million as of the date of the report but warns Nasdaq will continue to monitor ongoing compliance and could initiate delisting proceedings if compliance is not maintained at the time of its next periodic report. The filing also includes standard forward-looking statement disclaimers referencing the company's annual and quarterly reports.
BioCardia, Inc. filed a Current Report stating that, as of the report date, it believes it has regained compliance with Nasdaq's minimum $2.5 million stockholders' equity requirement for continued listing. The company notes that stockholders' equity exceeds $2.5 million as of the date of the report but warns Nasdaq will continue to monitor ongoing compliance and could initiate delisting proceedings if compliance is not maintained at the time of its next periodic report. The filing also includes standard forward-looking statement disclaimers referencing the company's annual and quarterly reports.
Simon H. Stertzer, a director of BioCardia, Inc. (BCDA), reported purchases and related holdings on Form 4. He participated in a public offering that closed on 09/19/2025, purchasing 398,400 shares of common stock at $1.25 per share and receiving 398,400 warrants exercisable into one share each at $1.25. The warrants are dated 09/19/2025 and expire 09/20/2027. After the reported transactions the filing shows 591,054 shares beneficially owned indirectly by entities tied to the reporting person, and several pre-existing holdings across trusts and LLCs are disclosed. The Form 4 is signed by power of attorney on 09/23/2025.
Simon H. Stertzer, a director of BioCardia, Inc. (BCDA), reported purchases and related holdings on Form 4. He participated in a public offering that closed on 09/19/2025, purchasing 398,400 shares of common stock at $1.25 per share and receiving 398,400 warrants exercisable into one share each at $1.25. The warrants are dated 09/19/2025 and expire 09/20/2027. After the reported transactions the filing shows 591,054 shares beneficially owned indirectly by entities tied to the reporting person, and several pre-existing holdings across trusts and LLCs are disclosed. The Form 4 is signed by power of attorney on 09/23/2025.
BioCardia insider purchase reported on Form 4: Director Andrew Scott (reporting as Andy Blank Revocable Living Trust) purchased 288,000 shares of common stock and received 288,000 warrants on 09/19/2025 at a price of $1.25 per share/warrant bundle. After the transaction the reporting person beneficially owned 634,023 shares (direct/indirect holdings) and held warrants exercisable into 288,000 shares expiring 09/20/2027. The filing notes the shares are held in a revocable trust for which the reporting person is trustee. The Form 4 was signed by power of attorney on 09/23/2025.
BioCardia insider purchase reported on Form 4: Director Andrew Scott (reporting as Andy Blank Revocable Living Trust) purchased 288,000 shares of common stock and received 288,000 warrants on 09/19/2025 at a price of $1.25 per share/warrant bundle. After the transaction the reporting person beneficially owned 634,023 shares (direct/indirect holdings) and held warrants exercisable into 288,000 shares expiring 09/20/2027. The filing notes the shares are held in a revocable trust for which the reporting person is trustee. The Form 4 was signed by power of attorney on 09/23/2025.
Insider purchase reported for BioCardia, Inc. (BCDA). Peter Altman, the company's President, CEO and a director, purchased 48,000 shares of common stock at $1.25 per share on 09/19/2025 through a public offering that closed that day, and received 48,000 warrants exercisable at $1.25 expiring 09/20/2027. After the transaction Mr. Altman beneficially owned 216,762 shares of common stock and 143,612 derivative securities (warrants/options) on a direct basis. The Form 4 was signed under power of attorney on 09/23/2025.
Insider purchase reported for BioCardia, Inc. (BCDA). Peter Altman, the company's President, CEO and a director, purchased 48,000 shares of common stock at $1.25 per share on 09/19/2025 through a public offering that closed that day, and received 48,000 warrants exercisable at $1.25 expiring 09/20/2027. After the transaction Mr. Altman beneficially owned 216,762 shares of common stock and 143,612 derivative securities (warrants/options) on a direct basis. The Form 4 was signed under power of attorney on 09/23/2025.